PUBLICATION REGISTRY

Go to research.

Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.

Publikationer som ChEBI hänvisar till för soblidotin. Visa hela publikationsregistret

A publication hit is not a conclusion. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.

Publications in the selection

28 hits

Bibliografisk träff 2020-11-05

Is Crocin a Potential Anti-tumor Candidate Targeting Microtubules? Computational Insights From Molecular Docking and Dynamics Simulations.

Wang Z, Ren J, Jin N, Liu X, Li X.

Front Mol Biosci · research-article; journal article · DOI 10.3389/fmolb.2020.586970

Bibliografisk träff 2019-03-21

Chemical Reactivity Theory and Empirical Bioactivity Scores as Computational Peptidology Alternative Tools for the Study of Two Anticancer Peptides of Marine Origin.

Frau J, Flores-Holguín N, Glossman-Mitnik D.

Molecules · research-article; journal article · DOI 10.3390/molecules24061115

Bibliografisk träff 2016-04-28

Novel Azetidine-Containing TZT-1027 Analogues as Antitumor Agents.

Yan Q, Wang Y, Zhang W, Li Y.

Mar Drugs · research-article; journal article · DOI 10.3390/md14050085

Bibliografisk träff 2010-02-09

Blockade of the extracellular signal-regulated kinase pathway enhances the therapeutic efficacy of microtubule-destabilizing agents in human tumor xenograft models.

Watanabe K, Tanimura S, Uchiyama A, Sakamoto T, Kawabata T, Ozaki K, Kohno M.

Clin Cancer Res · research support, non-u.s. gov't; journal article · DOI 10.1158/1078-0432.ccr-09-2482

Bibliografisk träff 2009-02-01

Phase I study of TZT-1027, a novel synthetic dolastatin 10 derivative and inhibitor of tubulin polymerization, given weekly to advanced solid tumor patients for 3 weeks.

Yamamoto N, Andoh M, Kawahara M, Fukuoka M, Niitani H.

Cancer Sci · research-article; clinical trial, phase i; journal article · DOI 10.1111/j.1349-7006.2008.01023.x

Bibliografisk träff 2008-01-23

Phase I study of TZT-1027, a novel synthetic dolastatin 10 derivative, for the treatment of patients with non-small cell lung cancer.

Horti J, Juhasz E, Monostori Z, Maeda K, Eckhardt S, Bodrogi I.

Cancer Chemother Pharmacol · clinical trial, phase i; journal article · DOI 10.1007/s00280-007-0665-7

Bibliografisk träff 2007-11-01

The inhibitory effect of docetaxel and p38 MAPK inhibitor on TZT-1027 (Soblidotin)-induced antivascular activity.

Watanabe J, Natsume T, Kobayashi M.

Anticancer Res · journal article

Bibliografisk träff 2007-09-01

Comparison of the antivascular and cytotoxic activities of TZT-1027 (Soblidotin) with those of other anticancer agents.

Watanabe J, Natsume T, Kobayashi M.

Anticancer Drugs · comparative study; journal article · DOI 10.1097/cad.0b013e3280dce1d1

Bibliografisk träff 2007-05-01

The novel microtubule-interfering agent TZT-1027 enhances the anticancer effect of radiation in vitro and in vivo.

Akashi Y, Okamoto I, Suzuki M, Tamura K, Iwasa T, Hisada S, Satoh T, Nakagawa K, Ono K, Fukuoka M.

Br J Cancer · research-article; evaluation study; journal article · DOI 10.1038/sj.bjc.6603769

Bibliografisk träff 2007-03-01

Antiangiogenic activity of TZT-1027 (soblidotin) on chick chorioallantoic membrane and human umbilical vein endothelial cells.

Watanabe J, Endo Y, Shimada N, Natsume T, Sasaki T, Kobayashi M.

In Vivo · journal article

Bibliografisk träff 2007-01-31

Tumor-specific antivascular effect of TZT-1027 (Soblidotin) elucidated by magnetic resonance imaging and confocal laser scanning microscopy.

Natsume T, Watanabe J, Ogawa K, Yasumura K, Kobayashi M.

Cancer Sci · journal article · DOI 10.1111/j.1349-7006.2007.00418.x

Bibliografisk träff 2006-12-01

Phase II study of intravenous TZT-1027 in patients with advanced or metastatic soft-tissue sarcomas with prior exposure to anthracycline-based chemotherapy.

Patel S, Keohan ML, Saif MW, Rushing D, Baez L, Feit K, DeJager R, Anderson S.

Cancer · clinical trial, phase ii; journal article · DOI 10.1002/cncr.22334

Bibliografisk träff 2006-11-30

Phase I study of TZT-1027, a novel synthetic dolastatin 10 derivative and inhibitor of tubulin polymerization, which was administered to patients with advanced solid tumors on days 1 and 8 in 3-week courses.

Tamura K, Nakagawa K, Kurata T, Satoh T, Nogami T, Takeda K, Mitsuoka S, Yoshimura N, Kudoh S, Negoro S, Fukuoka M.

Cancer Chemother Pharmacol · multicenter study; clinical trial, phase i; journal article · DOI 10.1007/s00280-006-0382-7

Bibliografisk träff 2006-11-07

A phase 2 study of TZT-1027, administered weekly to patients with advanced non-small cell lung cancer following treatment with platinum-based chemotherapy.

Riely GJ, Gadgeel S, Rothman I, Saidman B, Sabbath K, Feit K, Kris MG, Rizvi NA.

Lung Cancer · clinical trial, phase ii; research support, non-u.s. gov't; journal article · DOI 10.1016/j.lungcan.2006.10.002

Bibliografisk träff 2006-09-25

Antivascular effects of TZT-1027 (Soblidotin) on murine Colon26 adenocarcinoma.

Watanabe J, Natsume T, Kobayashi M.

Cancer Sci · research-article; journal article · DOI 10.1111/j.1349-7006.2006.00330.x

Bibliografisk träff 2006-05-01

Antitumor activity of TZT-1027 (Soblidotin).

Watanabe J, Minami M, Kobayashi M.

Anticancer Res · journal article

Bibliografisk träff 2006-03-21

Reference profiling of the genomic response induced by an antimicrotubule agent, TZT-1027 (Soblidotin), in vitro.

Shimoyama T, Hamano T, Natsume T, Koizumi F, Kiura K, Tanimoto M, Nishio K.

Pharmacogenomics J · research support, non-u.s. gov't; journal article · DOI 10.1038/sj.tpj.6500386

Bibliografisk träff 2006-03-01

Combination effect of TZT-1027 (Soblidotin) with other anticancer drugs.

Natsume T, Watanabe J, Horiuchi T, Kobayashi M.

Anticancer Res · journal article

Bibliografisk träff 2005-09-01

Total assignment of the (1)H- and (13)C-NMR spectra for TZT-1027 and related compounds.

Uchida H, Nishiyama T, Keino K, Seki T, Miyazaki K, Shiraiwa M.

Chem Pharm Bull (Tokyo) · journal article · DOI 10.1248/cpb.53.1190

Bibliografisk träff 2005-05-01

Phase I and pharmacokinetic study of the dolastatin 10 analogue TZT-1027, given on days 1 and 8 of a 3-week cycle in patients with advanced solid tumors.

de Jonge MJ, van der Gaast A, Planting AS, van Doorn L, Lems A, Boot I, Wanders J, Satomi M, Verweij J.

Clin Cancer Res · clinical trial; clinical trial, phase i; journal article · DOI 10.1158/1078-0432.ccr-04-1937

Bibliografisk träff 2004-07-01

TZT-1027 elucidates antitumor activity through direct cytotoxicity and selective blockade of blood supply.

Hashiguchi N, Kubota T, Koh J, Yamada Y, Saikawa Y, Otani Y, Watanabe M, Kumai K, Kitajima M, Watanabe J, Kobayashi M.

Anticancer Res · journal article

Bibliografisk träff 2003-09-01

Antitumor activity of TZT-1027 (Soblidotin) against vascular endothelial growth factor-secreting human lung cancer in vivo.

Natsume T, Watanabe J, Koh Y, Fujio N, Ohe Y, Horiuchi T, Saijo N, Nishio K, Kobayashi M.

Cancer Sci · research support, non-u.s. gov't; journal article · DOI 10.1111/j.1349-7006.2003.tb01526.x

Bibliografisk träff 2001-10-01

Validation of an analytical method for a potent antitumor agent, TZT-1027, in plasma using liquid chromatography-mass spectrometry.

Ochiai H, Mori H, Murata H, Seki T, Araki K, Kawabe Y, Miyazaki K, Tsukamoto K, Iwamura S.

J Chromatogr B Biomed Sci Appl · validation study; journal article · DOI 10.1016/s0378-4347(01)00360-7

Bibliografisk träff 2000-10-01

Induction of apoptosis in human cancer cells by TZT-1027, an antimicrotubule agent.

Watanabe J, Natsume T, Fujio N, Miyasaka K, Kobayashi M.

Apoptosis · journal article · DOI 10.1023/a:1009687609330

Bibliografisk träff 2000-08-01

TZT-1027, an antimicrotubule agent, attacks tumor vasculature and induces tumor cell death.

Otani M, Natsume T, Watanabe JI, Kobayashi M, Murakoshi M, Mikami T, Nakayama T.

Jpn J Cancer Res · research-article; journal article · DOI 10.1111/j.1349-7006.2000.tb01022.x

Bibliografisk träff 2000-07-01

Characterization of the interaction of TZT-1027, a potent antitumor agent, with tubulin.

Natsume T, Watanabe J, Tamaoki S, Fujio N, Miyasaka K, Kobayashi M.

Jpn J Cancer Res · comparative study; research-article; journal article · DOI 10.1111/j.1349-7006.2000.tb01007.x

Bibliografisk träff 1999-10-01

[Activity of a novel antitumor agent, TZT-1027].

Kobayashi M, Natsume T, Watanabe J, Fujio N, Mikami T, Miyasaka K, Tsukagoshi S.

Nihon Yakurigaku Zasshi · journal article; english abstract · DOI 10.1254/fpj.114.supplement_230

Bibliografisk träff 1997-03-01

Antitumor activity of TZT-1027, a novel dolastatin 10 derivative.

Kobayashi M, Natsume T, Tamaoki S, Watanabe J, Asano H, Mikami T, Miyasaka K, Miyazaki K, Gondo M, Sakakibara K, Tsukagoshi S.

Jpn J Cancer Res · comparative study; research support, non-u.s. gov't; research-article; journal article · DOI 10.1111/j.1349-7006.1997.tb00383.x